Specific investments recommended by advisers on pages 6 through 9 (in each issue, you’ll find them highlighted in blue) are tracked below for one year, until the adviser no longer would buy the investment or until he or she no longer covers it–whichever comes first. It is our hope, however, that many of the investments on this page will prove to be profitable long-term performers, so investors need not sell a holding simply because a year has passed since its original recommendation.



-Despite a fourth quarter squeeze, Heinz (NYSE: HZN) reported record sales and profits for its 2009 fiscal year. Full-year earnings per share (EPS) rose 10.3 percent to $2.90 as net income increased 9.2 percent over the prior year to $923 million. Sales of its top 15 brands were up 7.4 percent, with its iconic ketchup contributing 9.1 percent of that growth. Despite that solid performance and expectations for continued growth, the company issued weaker than expected earnings guidance for FY 2010, projecting EPS between $2.60 and $2.70 for the full year. With sales in more 200 countries around the world, the company anticipates that volatility in currency markets will weigh on earnings.

-Best known for its work in developing medications for humans, Pfizer (NYSE: PFE) recently gained FDA approval for Palladia, the first cancer treatment specifically developed for man’s best friend. All of the cancer treatments currently available for dogs were originally developed for humans, but as spending on pet health care has continued to trend upwards in recent years developing medications aimed specifically at animals is becoming an extremely lucrative business.

–Chevron (NYSE: CVX) has announced that it will sell its fuel marketing operations in Haiti and Kenya to Medley Capital Limited and the Kenyan unit of Total, respectively. While the value of the deals has not yet been announced, the move is in line with Chevron’s realignmentof its operations to areas of greater opportunity around the world, as well as to more politically stable regions.

–Apple (AAPL) is facing an antitrust probe launched by the Justice Dept alleging that the firm colluded with Google (NSDQ: GOOG), Yahoo (NSDQ: YHOO) and biotech Genentech (NYSE: DNA) to enter into agreements to not poach top talent from one another. The investigation comes on the heels of the recently announced inquiry into ties between the boards of directors of Apple and Google. Many insiders believe that little will come of the investigations and that they’re more for show than part of a meaningful regulatory program. Many do agree than Apple could be at some risk, though, based on allegations that it and some of the wireless carriers with which it partners may be working to block certain free applications on their devices that compete with their paid offerings.